At the time of writing, Aytu BioPharma Inc [AYTU] stock is trading at $1.97, saw in change for the day. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The AYTU shares have gain 2.07% over the last week, with a monthly amount drifted -1.50%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Aytu BioPharma Inc [NASDAQ: AYTU] stock has seen the most recent analyst activity on March 30, 2021, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $11. Previously, H.C. Wainwright started tracking the stock with Buy rating on May 29, 2020, and set its price target to $3.
For the past year, the stock price of Aytu BioPharma Inc fluctuated between $0.95 and $2.99. Aytu BioPharma Inc [NASDAQ: AYTU] shares were valued at $1.97 at the most recent close of the market.
Analyzing the AYTU fundamentals
According to Aytu BioPharma Inc [NASDAQ:AYTU], the company’s sales were 69.22M for trailing twelve months, which represents an 2.55% jump. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -0.06%, Pretax Profit Margin comes in at 0.03%, and Net Profit Margin reading is 0.02%. To continue investigating profitability, this company’s Return on Assets is posted at 0.01, Equity is 0.05 and Total Capital is -0.07. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.9177 points at the first support level, and at 1.8655 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.0345, and for the 2nd resistance point, it is at 2.0991.
Ratios To Look Out For
It is important to note that Aytu BioPharma Inc [NASDAQ:AYTU] has a current ratio of 1.03. In addition, the Quick Ratio stands at 0.87 and the Cash Ratio stands at 0.26. Considering the valuation of this stock, the price to sales ratio is 0.18, the price to book ratio is 0.35.
Transactions by insiders
Recent insider trading involved Disbrow Jarrett, Chief Business Officer, that happened on Jun 09 ’25 when 16666.0 shares were purchased. Chief Executive Officer, Disbrow Joshua R. completed a deal on Jun 09 ’25 to buy 66666.0 shares. Meanwhile, Chief Executive Officer Disbrow Joshua R. bought 15000.0 shares on Feb 28 ’25.